InVivoSIM anti-human PD-1 (Pembrolimumab Biosimilar)

Clone Pembrolimumab
Catalog # SIM0010
Category InVivoSIM™ Biosimilar Antibodies
Price
Size Regular Price
1mg $ 205.00
5mg $ 795.00
25mg $ 2,775.00
50mg $ 3,990.00
100mg $ 5,575.00
About InVivoSIM anti-human PD-1 (Pembrolimumab Biosimilar)

This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Pembrolimumab making it ideal for research use. This Pembrolimumab biosimilar reacts with human PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily. PD-1 is transiently expressed on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. PD-1 expression declines after successful elimination of antigen. Additionally, Pdcd1 mRNA is expressed in developing B lymphocytes during the pro-B-cell stage. PD-1’s structure includes a ITIM (immunoreceptor tyrosine-based inhibitory motif) suggesting that PD-1 negatively regulates TCR signals. PD-1 signals via binding its two ligands, PD-L1 and PD-L2 both members of the B7 family. Upon ligand binding, PD-1 signaling inhibits T-cell activation, leading to reduced proliferation, cytokine production, and T-cell death. Additionally, PD-1 is known to play key roles in peripheral tolerance and prevention of autoimmune disease. Induced PD-L1 expression is common in many tumors including squamous cell carcinoma, colon adenocarcinoma, and breast adenocarcinoma. PD-L1 overexpression results in increased resistance of tumor cells to CD8 T cell mediated lysis. PD-L1 overexpression results in increased resistance of tumor cells to CD8 T cell mediated lysis. In experimental models of melanoma, tumor growth can be transiently arrested via treatment with antibodies which block the interaction between PD-L1 and its receptor PD-1. For these reasons anti-PD-1 mediated immunotherapies are currently being used as cancer treatments. Pembrolimumab binds to PD-1 on activated immune cells to selectively block the interaction of PD-1 with its ligands. 

InVivoSIM anti-human PD-1 (Pembrolimumab Biosimilar) Specifications
Isotypehuman IgG4
ImmunogenHuman PD-1
Reported Applications
  • Blocking of PD-1/PD-L signaling
  • Functional assays
Formulation
  • PBS, pH 7.0
  • Contains no stabilizers or preservatives
Endotoxin
  • <1EU/mg (<0.001EU/μg)
  • Determined by LAL gel clotting assay
Aggregation
  • <5%
  • Determined by DLS
Purity
  • >95%
  • Determined by SDS-PAGE
Sterility0.2 μM filtered
ProductionPurified from cell culture supernatant
PurificationProtein A
Molecular Weight150 kDa
Murine Pathogen Test Results
  • Mouse Norovirus: Negative
  • Mouse Parvovirus: Negative
  • Mouse Minute Virus: Negative
  • Mouse Hepatitis Virus: Negative
  • Reovirus Screen: Negative
  • Lymphocytic Choriomeningitis virus: Negative
  • Lactate Dehydrogenase-Elevating Virus: Negative
  • Mouse Rotavirus: Negative
  • Theiler’s Murine Encephalomyelitis: Negative
  • Ectromelia/Mousepox Virus: Negative
  • Hantavirus: Negative
  • Polyoma Virus: Negative
  • Mouse Adenovirus: Negative
  • Sendai Virus: Negative
  • Mycoplasma Pulmonis: Negative
  • Pneumonia Virus of Mice: Negative
  • Mouse Cytomegalovirus: Negative
  • K Virus: Negative
StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
Application References